# Target Sequencing and Resequencing Market > Target Sequencing and Resequencing Market Research Report By Target Sequencing Type (Whole Genome Sequencing, Exome Sequencing, Targeted Panel Sequencing, Single-Gene Sequencing), By Technology (Next-Generation Sequencing (NGS), Single-Molecule Real-Time (SMRT) Sequencing, Ion Torrent Sequencing, Nanopore Sequencing), By Application (Diagnostic Testing, Pharmaceutical Development, Agricultural Research, Forensic Science, Personalized Medicine) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.18% - **2024:** $ 42.05 Billion - **2025:** $ 47.59 Billion - **2035:** $ 164.17 Billion - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), BGI Genomics (CN), Qiagen (DE), PerkinElmer (US), Oxford Nanopore Technologies (GB), Genomatix (DE) **Report ID:** MRFR/HC/28498-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/target-sequencing-and-resequencing-market-30243 --- ## Market Summary ## **Target Sequencing and Resequencing Market Overview** As per MRFR analysis, the Target Sequencing Resequencing Market Size was estimated at 42.05 (USD Billion) in 2024. The Target Sequencing Resequencing Market Industry is expected to grow from 47.59 (USD Billion) in 2025 to 145.05 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034). ### **Key Target Sequencing and Resequencing Market Trends Highlighted** Target Sequencing and Resequencing are experiencing advancements in technology, such as benchtop sequencers, nanopore technology, and single-cell sequencing. These breakthroughs enable researchers to sequence larger genomes and study complex genetic variations with higher accuracy and throughput. The rise of precision medicine and personalized healthcare is driving demand for target sequencing to identify genetic predispositions, diagnose diseases, and guide treatment strategies. Additionally, the increasing adoption of next-generation sequencing (NGS) platforms, coupled with decreasing sequencing costs, is facilitating the widespread use of Target Sequencing and Resequencing. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Target Sequencing and Resequencing Market Drivers** ### **Advancements in Sequencing Technologies Drive Market Growth** It is true that the Target Sequencing and Resequencing Market Industry is on a growth path. This growth is attributed to advancements in sequencing technologies. As noted by Technological Networks, Next-generation sequencing and whole-genome sequencing have been one of the developed areas in the fields of genomics. Researchers and clinicians can now determine genetic variations and mutations responsible for or associated with certain diseases. For instance, the NGS technology which uses Illumina's MiSeq and HiSeq systems and PacBio’s SMRT sequencing technology has led to an increase in sequencing throughput and a decrease in the cost of sequencing technologies. The reduction in sequencing has made Target Sequencing and Resequencing more common. Moreover, the decline has shown advancement in precision diagnostics and personalized medicine. ### **Growing Prevalence of Genetic Disorders and Diseases** The increasing prevalence of genetic disorders and diseases worldwide is another major factor driving the growth of the Target Sequencing and Resequencing Market Industry. Genetic disorders are caused by mutations or variations in genes, and they can range from rare conditions to common diseases such as cancer and heart disease. The rising incidence of these disorders has led to an increased demand for genetic testing, including Target Sequencing and Resequencing, to identify the underlying genetic causes and develop appropriate treatment strategies. This has created a significant opportunity for the growth of the Target Sequencing and Resequencing Market Industry. ### **Government Initiatives and Funding Support Research and Development** Government initiatives and funding play a crucial role in supporting research and development in the Target Sequencing and Resequencing Market Industry. Governments worldwide recognize the importance of genomics in improving healthcare outcomes and reducing the burden of genetic diseases. They provide funding for research projects, establish research centers, and implement policies that encourage collaboration between academia and industry. This support fosters innovation and enables researchers to develop new and improved Target Sequencing and Resequencing technologies, which ultimately contribute to the growth of the Target Sequencing and Resequencing Market Industry. ## **Target Sequencing and Resequencing Market Segment Insights** ### **Target Sequencing and Resequencing Market Target Sequencing Type Insights** Type Based Segmentation The Target Sequencing and Resequencing market is segmented based on the target sequencing type into whole genome sequencing, exome sequencing, targeted panel sequencing, and single-gene sequencing. Among these, whole genome sequencing held the largest market share in 2023, accounting for over 40% of the global revenue. This is due to the ability of the whole genome sequencing process to provide a comprehensive analysis of the entire genome, including both coding and non-coding regions. As such, this type of target sequencing is majorly used in various research studies and clinical diagnostics for identifying and elucidating genetic variants that contribute to complex diseases and disorders. Exome sequencing is another significant segment of the market, which accounted for around 30% of the market share in 2023 due to lesser expense and time consuming in comparison to the whole genome sequencing process. Exome sequencing captures the exonic component through target enrichment, which exclusively targets the sequencing of only the protein-coding regions of the genome. As a result, exome sequencing is majorly employed to identify disease-causing genetic variants associated with Mendelian disorders and certain types of cancer, thus acting as an attractive option for clinical studies. Another type of target sequencing, titled targeted panel sequencing, is relatively lower on the adoption pedal. This approach sequences only the selected set of genes that are known to be associated with the target disease. For this reason, it is highly targeted and cost-effective, making it specifically ideal in clinical diagnostics, pharmacogenomics, and personalized medicine. Lastly, single-gene sequencing is the most specific, as well as cost-effective, approach where only one gene is targeted for sequencing. This is commonly done to identify mutations associated with specific inherited disorders, including cystic fibrosis and sickle cell anemia. Projected growth The prime driving factors of the Target Sequencing and Resequencing market include expanding adoption of personalized medicine approaches, technological advancements, and rising incidences of genetic disorders. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Target Sequencing and Resequencing Market Technology Insights** The Target Sequencing and Resequencing market is expected to witness significant growth in the coming years, driven by the increasing demand for personalized medicine and the growing adoption of next-generation sequencing (NGS) technologies. NGS is a high-throughput sequencing technology that allows for the rapid and cost-effective sequencing of large amounts of DNA or RNA. It has revolutionized the field of genomics and has enabled a wide range of applications, including Target Sequencing and Resequencing. Target sequencing is a technique used to sequence specific regions of the genome, such as genes or exomes. It is commonly used for the identification of genetic variants associated with diseases and for the development of personalized treatment plans. Resequencing is a technique used to sequence the entire genome of an individual, and it is often used for research purposes to identify genetic variants that may be associated with complex diseases. The Target Sequencing and Resequencing market is segmented based on technology, application, and end-user. In terms of technology, the market is segmented into NGS, single-molecule real-time (SMRT) sequencing, Ion Torrent sequencing, and nanopore sequencing. NGS is the most widely used technology for Target Sequencing and Resequencing, and it is expected to continue to dominate the market in the coming years. SMRT sequencing is a newer technology that offers longer read lengths than NGS, and it is expected to gain market share in the coming years. Ion Torrent sequencing and nanopore sequencing are other emerging technologies that are expected to contribute to the growth of the Target Sequencing and Resequencing market. ### **Target Sequencing and Resequencing Market Application Insights** The application segment plays a crucial role in driving the growth of the Target Sequencing and Resequencing Market. Diagnostic testing accounted for the largest market share in 2023, and it is projected to maintain its dominance throughout the forecast period. The increasing prevalence of genetic disorders and the need for accurate and timely diagnosis are major factors contributing to the growth of this segment. Pharmaceutical development is another significant application segment, with a growing demand for Target Sequencing and Resequencing in drug discovery and personalized medicine. The agricultural research segment is also witnessing significant growth due to its applications in crop improvement and livestock breeding. Forensic science and personalized medicine are other key application segments that are expected to contribute to the overall growth of the Target Sequencing and Resequencing Market in the coming years. ### **Target Sequencing and Resequencing Market Regional Insights** The regional segmentation of the Target Sequencing and Resequencing Market showcases diverse market dynamics and growth patterns. North America holds a significant market share, driven by advanced healthcare infrastructure, extensive research and development activities, and a high prevalence of genetic disorders. Europe follows closely, with a robust healthcare system, government initiatives supporting genomics research, and a growing demand for personalized medicine. The Asia-Pacific (APAC) region is expected to witness substantial growth, fueled by rising healthcare expenditure, increasing awareness of genetic testing, and government investments in healthcare infrastructure. South America and the Middle East and Africa (MEA) regions present growth opportunities due to the increasing adoption of advanced technologies and the rising prevalence of genetic diseases. These regional insights are crucial for businesses operating in the Target Sequencing and Resequencing Market, enabling them to tailor their strategies and capitalize on growth opportunities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Target Sequencing and Resequencing Market Key Players and Competitive Insights** Major market players in the Target Sequencing and Resequencing Market industry constantly strive to gain a competitive advantage by developing new products and technologies. Moreover, leading players of the Target Sequencing and Resequencing Market pursue diversification of their zones of operation and development of mutually beneficial partnerships with other companies. The Target Sequencing and Resequencing Market industry is expected to develop in the future due to the rising demand for personalized medicine and the appearance of new targeted medications. The Target Sequencing and Resequencing Market will remain a highly competitive market segment, where several big players will compete for their market share. Illumina is the leading provider of sequencing and array-based solutions for genetic analysis. The product range and services of the company are extensive and include the development of the NextSeq series of sequencers, including the NextSeq 550 and the NextSeq 500 series. Besides, the company has developed the TruSeq library preparation kits and has therefore accumulated a large global customer base, as its clients are academic institutions, pharmaceutical companies, and clinical laboratories. Agilent Technologies is the company specializing in the development and manufacturing of instruments, software, and consumables for life sciences research and analysis. The Target Sequencing and Resequencing service and product line of the Agilent Technologies is also extensive and includes the development of the SureSelectXT target enrichment system and the Agilent NGS Workstation data analysis software. Agilent Technologies has a high image of a reliable company with reputably manufactured high-quality products and instruments, as a high number of researchers from the academic world, industry, and government use the Agilent products in their work. ### **Key Companies in the Target Sequencing and Resequencing Market Include** ## **Target Sequencing and Resequencing Industry Developments** The market growth is attributed to the increasing adoption of next-generation sequencing (NGS) technologies, the rising prevalence of chronic diseases, and the growing demand for personalized medicine. Key players in the market include Illumina, Inc., Pacific Biosciences of California, Inc., Thermo Fisher Scientific, Inc., and BGI Genomics Co., Ltd. Recent developments in the market include the launch of new products and services, such as Illumina's NovaSeq X Plus system and Pacific Biosciences' Sequel IIe system. These systems offer improved accuracy, speed, and throughput, which is expected to further drive market growth. Additionally, collaborations between market players and research institutions are expected to accelerate the development of new applications for Target Sequencing and Resequencing, thereby expanding the market's scope. ## **Target Sequencing and Resequencing Market Segmentation Insights** ### **Target Sequencing and Resequencing Market Target Sequencing Type Outlook** ### **Target Sequencing and Resequencing Market Technology Outlook** ### **Target Sequencing and Resequencing Market Application Outlook** ### **Target Sequencing and Resequencing Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Growing Applications in Oncology The growing applications of target sequencing in oncology represent a vital driver for the Target Sequencing and Resequencing Market. Cancer research increasingly relies on genomic data to identify mutations and tailor treatments for patients. Targeted therapies, which are designed to attack specific cancer cells based on their genetic makeup, have shown promising results in clinical trials. The market for targeted cancer therapies is projected to reach approximately 100 billion USD by 2026, underscoring the importance of genomic insights in oncology. As oncologists and researchers continue to leverage target sequencing technologies to enhance patient outcomes, the demand for these solutions is likely to expand, further propelling the growth of the target sequencing and resequencing market. ### Rising Demand for Precision Medicine The increasing emphasis on [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) is a pivotal driver for the Target Sequencing and Resequencing Market. As healthcare shifts towards personalized treatment plans, the need for accurate genetic information becomes paramount. This trend is evidenced by the projected growth of the precision medicine market, which is expected to reach approximately 217 billion USD by 2028. Target sequencing technologies enable healthcare providers to tailor therapies based on individual genetic profiles, thereby enhancing treatment efficacy. Furthermore, advancements in bioinformatics tools facilitate the analysis of complex genomic data, which is crucial for the development of personalized therapies. Consequently, the demand for target sequencing and resequencing solutions is likely to surge as healthcare systems increasingly adopt precision medicine approaches. ### Technological Innovations in Sequencing Technological innovations play a crucial role in shaping the Target Sequencing and Resequencing Market. The advent of next-generation sequencing (NGS) technologies has revolutionized genomic research, allowing for faster and more cost-effective sequencing. For instance, the cost of sequencing a human genome has dramatically decreased from over 100 million USD to less than 1,000 USD in recent years. This reduction in cost, coupled with enhanced accuracy and throughput, has made target sequencing more accessible to research institutions and clinical laboratories. Moreover, the integration of artificial intelligence and machine learning in data analysis is expected to further streamline workflows and improve the interpretation of genomic data. As these technologies continue to evolve, they are likely to drive the growth of the target sequencing and resequencing market. ### Increased Investment in Genomic Research The surge in investment in genomic research is a significant driver for the Target Sequencing and Resequencing Market. Governments and private entities are increasingly funding initiatives aimed at understanding genetic diseases and developing novel therapies. For example, the National Institutes of Health (NIH) has allocated substantial resources to genomic research, which has led to breakthroughs in understanding complex diseases. This influx of funding not only supports academic research but also stimulates the development of commercial applications in the target sequencing sector. As more organizations recognize the potential of genomics in addressing healthcare challenges, the demand for target sequencing and resequencing technologies is expected to rise, fostering innovation and collaboration within the industry. ### Regulatory Support for Genomic Technologies Regulatory support for genomic technologies is emerging as a key driver for the Target Sequencing and Resequencing Market. Regulatory bodies are increasingly recognizing the importance of genomic data in clinical decision-making and are establishing frameworks to facilitate the integration of these technologies into healthcare. For instance, the U.S. Food and Drug Administration (FDA) has introduced guidelines to streamline the approval process for genomic tests, thereby encouraging innovation in the field. This supportive regulatory environment not only fosters the development of new sequencing technologies but also enhances their adoption in clinical settings. As regulatory frameworks continue to evolve, they are likely to bolster the growth of the target sequencing and resequencing market, making these technologies more accessible to healthcare providers. ## Future Outlook The Target Sequencing and Resequencing Market is projected to grow at a 13.18% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for personalized medicine. **New opportunities:** - Development of integrated bioinformatics platforms for data analysis. Expansion of targeted therapies in oncology through advanced sequencing. Partnerships with healthcare providers for personalized genomic testing services. By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic collaborations. ## Segment Insights ### By Type: Whole Genome Sequencing (Largest) vs. Targeted Panel Sequencing (Fastest-Growing) The Target Sequencing and Resequencing Market is increasingly characterized by diverse segment values, with Whole Genome Sequencing (WGS) commanding the largest market share. WGS provides comprehensive insights into complete genomic information, appealing to a wide range of applications from research to [clinical diagnostics](https://www.marketresearchfuture.com/reports/clinical-diagnostic-market-41770). Following in the ranks, Exome Sequencing has established a significant presence by focusing on protein-coding regions, thereby garnering substantial attention from researchers and clinicians alike. Meanwhile, Targeted Panel Sequencing is rapidly gaining traction due to its ability to deliver specific, cost-effective analyses for particular diseases. As the demand for personalized medicine continues to rise, growth trends in the Target Sequencing and Resequencing Market reflect a dynamic shift toward more focused sequencing strategies. Targeted Panel Sequencing emerges as the fastest-growing segment, driven by advancements in technology that facilitate quicker and more accurate assessments of genetic variations. Furthermore, an increase in the prevalence of genetic disorders, coupled with the need for tailored therapeutic strategies, significantly propels this segment's growth. Innovations in assay technologies further enhance the efficiency of sequencing processes, ensuring that this segment attracts substantial investment and resources for continued development in the future. Whole Genome Sequencing (Dominant) vs. Exome Sequencing (Emerging) Whole Genome Sequencing (WGS) stands out as the dominant segment in the Target Sequencing and Resequencing Market due to its unrivaled ability to capture the comprehensive genetic landscape of organisms. WGS not only serves a wide variety of applications, including cancer genomics and inherited disorders but is also integral for large-scale population studies. Its widespread acceptance can be attributed to the continuous reduction in sequencing costs and enhancements in bioinformatics, making it accessible for broader clinical applications. Exome Sequencing, on the other hand, is recognized as an emerging segment, targeting only the protein-coding regions of the genome. While it does not provide the full breadth of information that WGS does, its focus allows for an efficient and cost-effective option for identifying disease-causing mutations, hence gaining popularity among researchers and clinicians. Exome Sequencing's growing role in diagnostics, particularly in rare disease studies, highlights its potential to complement WGS, catering to a distinct market need. ### By Technology: Next-Generation Sequencing (NGS) (Largest) vs. Single-Molecule Real-Time (SMRT) Sequencing (Fastest-Growing) The Target Sequencing and Resequencing Market showcases a significant distribution of market share across various technologies. Next-Generation Sequencing (NGS) holds the largest share, thanks to its high throughput and cost-effectiveness, making it the preferred choice for large-scale genomic studies. In contrast, Single-Molecule Real-Time (SMRT) Sequencing, while smaller in share, is rapidly gaining traction due to its unique ability to produce long reads, thereby enhancing the accuracy of complex genome assemblies. The growth trends within this segment are shaped by technological advancements and increasing research investments in genomics. NGS continues to dominate due to its extensive applications in clinical diagnostics and research, while SMRT Sequencing is emerging rapidly, driven by the need for precision medicine and complex genomic analysis. This dynamic landscape reflects the adaptability and evolution of sequencing technologies in response to scientific demands and funding initiatives. Technology: NGS (Dominant) vs. SMRT Sequencing (Emerging) Next-Generation Sequencing (NGS) stands as the dominant technology in the Target Sequencing and Resequencing Market, lauded for its rapid sequencing capabilities and scalability. It is widely adopted in various applications, including genomics, transcriptomics, and [epigenomics](https://www.marketresearchfuture.com/reports/epigenomics-market-12416), making it invaluable for researchers and clinicians. In contrast, Single-Molecule Real-Time (SMRT) Sequencing is an emerging technology that offers long-read capabilities, allowing for improved resolution of complex genomic regions and structural variations. While still gaining market share compared to NGS, SMRT Sequencing is viewed as a complementary approach, particularly beneficial for applications in personalized medicine and advancing genomic research. ### By Application: Diagnostic Testing (Largest) vs. Personalized Medicine (Fastest-Growing) In the Target Sequencing and Resequencing Market, the application segments exhibit diverse functionalities, with Diagnostic Testing representing the largest share. This application emphasizes the utility of sequencing technologies in identifying genetic diseases and monitoring infectious diseases. Following Diagnostic Testing, Personalized Medicine is rapidly gaining traction due to advancements in genomics that facilitate tailored therapies, indicating a shift in market demands towards more individualized treatment options. The growth trends within these segments are propelled by technological innovations and increased investments in genetic research. Diagnostic Testing continues to benefit from the rising prevalence of chronic diseases, leading to enhanced adoption of genomic tests. Meanwhile, Personalized Medicine is emerging swiftly, driven by the promise of improved patient outcomes and the integration of genetic information into treatment protocols. Diagnostic Testing (Dominant) vs. Personalized Medicine (Emerging) Diagnostic Testing is currently the dominant application in the Target Sequencing and Resequencing Market, given its critical role in clinical diagnostics and disease management. This segment leverages sequencing technologies to offer rapid results, enabling early detection and intervention. The growth of this segment is supported by regulatory approvals and the expansion of clinical laboratories. On the other hand, Personalized Medicine is viewed as an emerging application with significant potential for future growth. It focuses on utilizing genetic information to design individualized therapeutic strategies, making treatments more effective. As more healthcare providers adopt genomics in clinical practice, Personalized Medicine is set to revolutionize patient care, aligning with the trend towards customized healthcare solutions. ## Regional Market Share Analysis ### North America : Innovation and Leadership Hub North America is the largest market for target sequencing and resequencing, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, significant investments in genomics research, and a strong presence of key players like Illumina and Thermo Fisher Scientific. Regulatory support from agencies like the FDA further catalyzes market growth, driving demand for innovative sequencing technologies. The United States leads the market, followed by Canada, which is also witnessing growth due to increased funding for genomic research and development. The competitive landscape is characterized by the presence of major companies such as Roche and Agilent Technologies, which are continuously innovating to meet the rising demand for personalized medicine and targeted therapies. This dynamic environment fosters collaboration between academia and industry, enhancing the region's market position. ### Europe : Emerging Market with Potential Europe is the second-largest market for target sequencing and resequencing, accounting for approximately 30% of the global market share. The region is experiencing growth driven by increasing investments in genomics and personalized medicine, supported by favorable regulatory frameworks from the European Medicines Agency. Countries like Germany and the UK are at the forefront, pushing for advancements in genomic technologies and research initiatives. Germany leads the market, followed closely by the UK and France, which are also investing heavily in genomic research. The competitive landscape features key players such as Qiagen and Roche, who are focusing on innovative solutions to enhance sequencing accuracy and efficiency. Collaborative efforts between public and private sectors are fostering a robust environment for growth, positioning Europe as a significant player in the global market. ### Asia-Pacific : Rapidly Growing Market Asia-Pacific is witnessing rapid growth in the target sequencing and resequencing market, holding approximately 20% of the global market share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of personalized medicine, and government initiatives promoting genomics research. Countries like China and Japan are leading the charge, with significant investments in biotechnology and healthcare infrastructure. China is the largest market in the region, driven by the presence of companies like BGI Genomics, which is expanding its capabilities in sequencing technologies. Japan follows closely, with a strong focus on research and development in genomics. The competitive landscape is becoming increasingly dynamic, with both established players and startups innovating to capture market share, thereby enhancing the region's overall market potential. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa region is gradually emerging in the target sequencing and resequencing market, currently holding about 5% of the global market share. Growth is driven by increasing investments in healthcare infrastructure and a rising focus on genomics research. Countries like South Africa and the UAE are making strides in adopting advanced sequencing technologies, supported by government initiatives aimed at improving healthcare outcomes. South Africa is leading the market in the region, with a growing number of research institutions focusing on genomics. The competitive landscape is still developing, with a mix of local and international players entering the market. However, challenges such as regulatory hurdles and limited funding for research remain, which could impact the pace of growth in this region. ## Competitive Benchmarking The Target Sequencing and Resequencing Market is currently characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing demand for precision medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Roche (CH) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Illumina (US) focuses on enhancing its sequencing platforms, while Thermo Fisher Scientific (US) emphasizes expanding its portfolio through strategic acquisitions. Roche (CH) is investing heavily in R&D to develop next-generation sequencing technologies, which collectively shape a competitive environment that is increasingly reliant on innovation and strategic partnerships.The market structure appears moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency and reduce costs. This competitive structure allows for a diverse range of offerings, catering to different segments of the market, while the influence of key players remains substantial in setting industry standards and driving technological advancements. In August Illumina (US) announced the launch of its latest sequencing platform, which reportedly offers unprecedented accuracy and speed. This strategic move is likely to reinforce Illumina's market leadership by addressing the growing demand for high-throughput sequencing solutions in clinical and research settings. The introduction of this platform may also enhance the company's competitive edge against rivals by providing researchers with more efficient tools for genomic analysis. In September Thermo Fisher Scientific (US) completed the acquisition of a leading bioinformatics company, which is expected to bolster its capabilities in data analysis and interpretation. This acquisition signifies a strategic shift towards integrating advanced analytics into their sequencing solutions, potentially enhancing customer value and positioning Thermo Fisher as a comprehensive provider of genomic solutions. The move reflects a broader trend in the industry towards combining sequencing technologies with robust data analytics to facilitate precision medicine. In July Roche (CH) unveiled a new partnership with a prominent academic institution to develop innovative sequencing applications for oncology. This collaboration aims to leverage Roche's expertise in diagnostics and the academic institution's research capabilities, indicating a strategic focus on expanding its presence in the oncology market. Such partnerships are becoming increasingly vital as companies seek to enhance their product offerings and accelerate the development of targeted therapies. As of October the competitive trends in the Target Sequencing and Resequencing Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a crucial role in shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a future where innovation and quality will be paramount in determining market leadership. ## Recent News & Developments The market growth is attributed to the increasing adoption of next-generation sequencing (NGS) technologies, the rising prevalence of chronic diseases, and the growing demand for personalized medicine. Key players in the market include Illumina, Inc., Pacific Biosciences of California, Inc., Thermo Fisher Scientific, Inc., and BGI Genomics Co., Ltd. Recent developments in the market include the launch of new products and services, such as Illumina's NovaSeq X Plus system and Pacific Biosciences' Sequel IIe system. These systems offer improved accuracy, speed, and throughput, which is expected to further drive market growth. Additionally, collaborations between market players and research institutions are expected to accelerate the development of new applications for Target Sequencing and Resequencing Market, thereby expanding the market's scope. ## Report Scope | MARKET SIZE 2024 | 42.05(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 47.59(USD Billion) | | MARKET SIZE 2035 | 164.17(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.18% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), BGI Genomics (CN), Qiagen (DE), PerkinElmer (US), Oxford Nanopore Technologies (GB), Genomatix (DE) | | Segments Covered | Target Sequencing Type, Technology, Application, Regional | | Key Market Opportunities | Advancements in precision medicine drive demand for innovative solutions in the Target Sequencing and Resequencing Market. | | Key Market Dynamics | Technological advancements drive competitive forces, enhancing efficiency and accuracy in target sequencing and resequencing applications. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Target Sequencing and Resequencing Market by 2035?** A: The projected market valuation for the Target Sequencing and Resequencing Market by 2035 is 164.17 USD Billion. **Q: What was the overall market valuation of the Target Sequencing and Resequencing Market in 2024?** A: The overall market valuation of the Target Sequencing and Resequencing Market in 2024 was 42.05 USD Billion. **Q: What is the expected CAGR for the Target Sequencing and Resequencing Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Target Sequencing and Resequencing Market during the forecast period 2025 - 2035 is 13.18%. **Q: Which segment is projected to have the highest valuation in the Target Sequencing and Resequencing Market by 2035?** A: The Targeted Panel Sequencing segment is projected to reach a valuation of 60.0 USD Billion by 2035. **Q: What are the key applications driving growth in the Target Sequencing and Resequencing Market?** A: Key applications driving growth include Diagnostic Testing, Pharmaceutical Development, and Personalized Medicine. **Q: Which technology segment is expected to dominate the Target Sequencing and Resequencing Market by 2035?** A: Next-Generation Sequencing (NGS) is expected to dominate the market, reaching a valuation of 80.0 USD Billion by 2035. **Q: Who are the leading companies in the Target Sequencing and Resequencing Market?** A: Leading companies in the market include Illumina, Thermo Fisher Scientific, Roche, and Agilent Technologies. **Q: What was the valuation of the Exome Sequencing segment in 2024?** A: The valuation of the Exome Sequencing segment in 2024 was 8.0 USD Billion. **Q: How does the valuation of Single-Gene Sequencing compare to that of Targeted Panel Sequencing in 2024?** A: In 2024, Single-Gene Sequencing was valued at 9.05 USD Billion, whereas Targeted Panel Sequencing was valued at 15.0 USD Billion. **Q: What is the projected growth for the Nanopore Sequencing technology segment by 2035?** A: The Nanopore Sequencing technology segment is projected to grow to a valuation of 14.17 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/target-sequencing-and-resequencing-market-30243*